Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study. [electronic resource]
Producer: 20120316Description: 2591-2596 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Female
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Neoplasm Metastasis
- Polyethylene Glycols -- administration & dosage
- Receptor, ErbB-2 -- metabolism
- Trastuzumab
- Treatment Outcome
- Ventricular Dysfunction, Left -- chemically induced
- Ventricular Function, Left -- drug effects
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.